The expression and significance of KAI1 and Ki67 in bladder transitional cell carcinoma
MDR1/P-glycoprotein overexpression in bladder transitional cell carcinoma and its correlation with expression of survivin and Fa
OBJECTIVE To explore the expression of the MDR1/P-glycoprotein, Fas and survivin and to examine their correlation with the biologic behavior of bladder transitional cell carcinoma (BTCC).
To our knowledge, this HPV type has not been previously described in multifocal bladder transitional cell carcinoma in transplanted patients.
Using colony formation technique and KK-47 cell line established from a human bladder transitional cell carcinoma, the effects of 6 anticancer drugs, thio-TEPA, Bleomycin, mitomycin C, carbazilquinone, Adriamycin and cis-Platinum, were compared.
Selected risk factors for transitional cell bladder cancer
ABH isoantigens, histology and DNA ploidy in 36 consecutive patients with transitional cell bladder cancer.
Cell proliferation of transitional cell bladder cancer (TCC) was determined by MIB-1 immunolabeling, volume-corrected mitotic index (M/V index) and S-phase fraction measurement in 207 patients with superficial (Ta-T1) bladder cancer.
Fifteen patients with measurable metastatic transitional cell bladder cancer were treated with VP 16-213 100 mg/m2 IV daily for 4 days, repeated every 3 weeks.
So far, TN expression has not been described in transitional cell bladder cancer (TCC), and there is no information on the prognostic significance of its in situ expression.